Article

You have full text access to this OnlineOpen article

Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma

  1. Dr. Eugene M. McKelvey MD*,
  2. Jeffrey A. Gottlieb MD,
  3. Henry E. Wilson MD,
  4. Arthur Haut MD,
  5. Robert W. Talley MD,
  6. Ronald Stephens MD,
  7. Montague Lane MD,
  8. Jess F. Gamble MD,
  9. Stephen E. Jones MD,
  10. Petre N. Grozea MD,
  11. Jordon Gutterman MD,
  12. Charles Coltman Jr. MD,
  13. Thomas E. Moon PHD

Article first published online: 27 JUN 2006

DOI: 10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I

Issue

Cancer

Cancer

Volume 38, Issue 4, pages 1484–1493, October 1976

Additional Information

How to Cite

McKelvey, E. M., Gottlieb, J. A., Wilson, H. E., Haut, A., Talley, R. W., Stephens, R., Lane, M., Gamble, J. F., Jones, S. E., Grozea, P. N., Gutterman, J., Coltman, C. and Moon, T. E. (1976), Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer, 38: 1484–1493. doi: 10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I

Author Information

  1. University of Texas M. D. Anderson Hospital and Tumor Institute (CA03195, CA10376, CA10379), Ohio State University Hospitals (CA04920), University of Arkansas Medical Center (CA15995), Henry Ford Hospital (CA04915), University of Kansas Medical Center (CA12644), Baylor College of Medicine (CA03392, CA03161), University of Arizona College of Medicine (CA13612), Oklahoma Medical Research Foundation (CA16957, CA11233), and Wilford Hall USAF Medical Center

*Anderson Hospital and Tumor Institute, Houston, TX 77030

Publication History

  1. Issue published online: 27 JUN 2006
  2. Article first published online: 27 JUN 2006
  3. Manuscript Received: 30 DEC 1975

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (759K)

Abstract

Combination chemotherapy with CHOP (cyclophosphamide, Adriamycin, vin-cristine, and prednisone) and HOP (Adriamycin, vincristine, and prednisone) was used as treatment for patients with pathologically staged, advanced non-Hodgkin's lymphoma. Among 204 evaluable patients treated on CHOP there were 71% complete remissions with 92% overall responses. Among the 216 evaluable patients on HOP there were 61% complete remissions and 88% responses. Complete remission rates among patients with histiocytic lymphoma were comparable to those of patients with lymphocytic disease. Patients with nodular lymphoma had higher rates of complete remission than their counterparts with diffuse lymphoma. This was noted with both CHOP (78% vs. 67%) and HOP (67% vs. 60%) induction therapy. Rapid responses were common, as more than 14% of complete remissions and 66% of overall responses were achieved with the first course of treatment. Patients in complete remission have been maintained with either cyclophosphamide, vincristine, and prednisone (COP) or arabinosyl cytosine, vincristine, and prednisone (OAP). After 1 year, 86% of patients on COP and 80% on OAP are projected to be free of disease.

Get PDF (759K)